Spinal Muscular Atrophy IVF in Georgia: Applicable Conditions for PGT Screening of SMA

Physician Decision Logic: How I Assess When SMA Patients Consult About Georgia IVF

As a reproductive physician, when encountering consultations related to Spinal Muscular Atrophy (SMA) in the clinic, I do not give a direct "yes" or "no" answer. I first ask three questions: Have both partners completed genetic testing and identified the specific mutation type? Is it confirmed that one partner is affected or both are carriers? Is there a previous history of giving birth to a child with SMA? Because PGT technology for SMA is highly dependent on the precise identification of the pathogenic gene, and only under this premise can the IVF cycle in Georgia achieve true genetic prevention.

Such consultations have increased significantly after 2023, mainly because some provinces in China have included SMA in carrier screening programs. More couples receive genetic reports indicating they are "SMA carriers" and subsequently consider genetic screening options through IVF. Georgia, as an overseas IVF destination, has become a choice for some families due to its relatively lower medical costs and more relaxed embryo testing policies.

Spinal Muscular Atrophy (SMA) and PGT Screening: Direct Answers

Yes, it can be screened. Spinal Muscular Atrophy is a monogenic genetic disorder. Through PGT-M (Preimplantation Genetic Testing for Monogenic Disorders), a type of third-generation IVF technology (PGT, Preimplantation Genetic Testing), embryos can be screened for SMA pathogenic genes. Some certified reproductive medicine centers in Georgia have the capability to perform PGT-M, including embryo biopsy, single-cell whole-genome amplification, and pathogenic site detection.

However, the following conditions must be met:

• Both partners have completed genetic diagnosis, confirming the SMA pathogenic mutation (e.g., homozygous deletion or point mutation in exon 7 of the SMN1 gene);
• At least one partner (male or female) is a confirmed patient or carrier;
• The reproductive center in Georgia has the qualification for monogenic disease testing and can provide family linkage analysis or direct sequencing protocols.

Why are these conditions necessary? The detection principle of PGT-M is based on designing probes or amplification primers for known pathogenic sites. If the couple has not undergone genetic testing, the laboratory cannot establish a testing system and therefore cannot determine whether the embryo carries the pathogenic gene. Some centers in Georgia require patients to complete genetic diagnosis in their home country first, then have the report translated and notarized for laboratory evaluation.

Differences in SMA Screening Between Georgia and Other Countries

Different countries have varying regulations and technical levels for PGT, which directly affects the feasibility of SMA screening:

Advantages of Georgia: Relatively lower costs and fewer restrictions on embryo sex selection (some families consider gender selection, though it is unrelated to SMA itself). Note: Not all IVF institutions in Georgia have the capability for monogenic disease PGT. Some smaller institutions can only perform chromosomal aneuploidy screening (PGT-A) or simple structural rearrangements (PGT-SR) and cannot complete embryo diagnosis for monogenic diseases like SMA. Therefore, when choosing a hospital, it is necessary to specifically confirm "PGT-M" qualifications, rather than a general "third-generation IVF."

The Most Easily Overlooked Detail: Genetic Testing Must Be Completed in Advance

Many inquirers mistakenly believe that blood drawn in Georgia is sufficient for SMA genetic testing. This is a misconception. Embryo PGT-M requires first establishing the genetic profile of the couple, which usually takes 2-4 weeks for site confirmation and family verification. If the couple has not undergone testing themselves, or only one partner has been tested, the Georgian laboratory cannot directly initiate embryo screening. Specific materials required include:

• Complete SMA genetic testing reports for both partners (issued by the genetics department of a tertiary hospital in China, including SMN1 and SMN2 gene copy numbers);
• If there is a previous child with SMA, the child's genetic report (for linkage analysis);
• Family genetic history for at least three generations of both partners (some laboratories require this);
• Notarized translations into English or Russian (some centers in Georgia accept English reports).

Suggested Timeline: Genetic testing should ideally be completed 3 months before traveling to Georgia, with the paper report in hand. If the report involves special sites (e.g., point mutations rather than common deletions), an appointment with a genetic counselor for probe design evaluation may be needed, adding an extra 1-2 weeks.

The Most Common Pitfall: Assuming All Georgian Hospitals Can Perform PGT

Georgia's assisted reproductive industry has developed rapidly in recent years, but top-tier PGT laboratories are still concentrated in a few hospitals in the capital, Tbilisi. Some agencies or clinics may advertise "support for third-generation IVF," but in reality, only offer PGT-A (chromosomal number screening). Monogenic disease PGT-M requires specialized kits and laboratory processes, and the two technologies are very different.

How to identify? Ask the center to provide the number of monogenic disease PGT-M cases (e.g., SMA, thalassemia) completed in the past year. An experienced center can typically provide data from at least 20 cases. Also, inquire whether the laboratory collaborates with overseas genetic testing companies (e.g., Reprogenetics, Igenomix). If the answer is "samples are sent to a laboratory in Ukraine or Germany," consider the risks and additional costs of embryo freezing and transportation.

Another common trap: The hospital verbally promises "SMA screening can be done" but fails to inform that the couple needs to provide their own pathogenic site testing reagents. Some domestic patients carry rare mutations (e.g., point mutation c.889G>A), for which Georgia may not have ready-made detection probes. Customization is needed, taking about 1-2 months and adding 10,000-20,000 RMB in costs. Be sure to confirm with the laboratory whether they can cover your specific mutation type before signing the contract.

Suitable and Unsuitable Candidates

Suitable for considering SMA screening via Georgia IVF in the following situations:

• Both partners are carriers of the SMN1 gene exon 7 deletion (most common type, accounting for about 95%);
• One partner is an SMA patient (homozygous deletion), and the other is a non-carrier (but PGT-M is needed to test if the embryo carries the pathogenic gene);
• Previous child born with SMA, and the carrier sites of both partners are clearly identified;
• Limited financial budget (Georgia costs about one-third to one-half of those in the US);
• Acceptance of more relaxed embryo sex selection policies (some families also screen for X-linked genetic diseases, but SMA is autosomal recessive and unrelated to sex).

Unsuitable or requiring careful evaluation:

• Both partners have not completed genetic diagnosis, or reports are incomplete (only one partner's results);
• The pathogenic mutation carried by either partner is extremely rare, and the Georgian laboratory cannot design effective probes;
• Female partner is of advanced age (over 42), with diminished ovarian reserve, potentially unable to obtain enough blastocysts for PGT-M testing (usually at least 3-4 blastocysts are needed for a relatively high chance of finding a healthy embryo);
• Expecting 100% accuracy from PGT testing. Current PGT-M accuracy for monogenic diseases is about 96%-99%, with risks of false negatives due to mosaicism or allele dropout, requiring subsequent prenatal diagnosis (amniocentesis) for verification;
• Religious or ethical objections to embryo biopsy (some believe biopsy harms the embryo).

Actual Process and Timeline

From the initial consultation to embryo transfer, the complete process for SMA screening via Georgia IVF typically takes 4-6 months, including the following steps:

1. Genetic Counseling and Gene Confirmation (completed domestically, about 2-4 weeks): Complete SMA genetic testing at a formal genetics clinic, obtaining genetic reports for both partners and necessary family members.
2. Selecting a Georgian Reproductive Center (2-4 weeks): Investigate and confirm the center has PGT-M qualifications, send genetic reports for feasibility assessment, sign a contract, and pay a partial fee.
3. Pre-operative Examinations and File Creation (7-10 days after arriving in Georgia): Includes female endocrine tests, ovarian function (AMH, FSH, antral follicle count), male semen analysis, infectious disease screening, chromosome karyotype, etc. Documents: Passport (validity must cover the entire treatment cycle and embryo freezing storage), marriage certificate (some centers require notarized translation).
4. Ovarian Stimulation and Egg Retrieval (about 10-14 days): Starts on day 2 of the female's menstrual cycle using gonadotropin protocols. After egg retrieval, oocytes are fertilized via ICSI.
5. Embryo Culture and Biopsy (about 5-6 days): After blastocyst formation, 3-5 trophectoderm cells are taken from each embryo and sent to the PGT laboratory. Biopsied embryos are immediately cryopreserved (day 5/6 frozen embryos).
6. PGT-M Testing (about 2-4 weeks): The laboratory performs single-cell amplification and pathogenic site detection, issuing a report indicating "no pathogenic gene," "carrier," or "affected."
7. Transfer and Follow-up (next cycle after testing): Select healthy (normal or carrier) embryos for single blastocyst transfer. Pregnancy test 12-14 days after transfer. If pregnant, amniocentesis is recommended at 18-20 weeks of gestation for verification.

Frequently Asked Question: "Is PGT-M worthwhile if I only have 2 embryos?" From a genetic perspective, even 2 embryos have screening value, but there is a risk that both embryos could be affected or carriers, resulting in no embryo for transfer. Clinically, it is most cost-effective to proceed with PGT-M when at least 3-4 blastocysts are available.

Risk Reminders and Special Population Considerations

Risk Reminder: No PGT technology can achieve 100% prevention of genetic diseases. The current laboratory misdiagnosis rate for PGT-M is about 0.5%-1%, mainly due to allele dropout (ADO), contamination, or mosaicism. Therefore, all PGT-M pregnancies must undergo prenatal diagnosis (amniocentesis or chorionic villus sampling); prenatal testing should not be omitted due to IVF screening.

Examination Reminder: For women over 38 years old or with a history of ovarian surgery, it is advisable to have an AMH and antral follicle count done domestically 1-2 months in advance. After evaluation, discuss with the doctor whether a mild stimulation protocol or cumulative cycles are needed. Some hospitals in Georgia may recommend 1-2 egg retrievals first, freezing all embryos before unified biopsy and testing, to increase the probability of ultimately obtaining a healthy embryo.

Special Population Reminder: If both partners are SMA carriers but have not been pregnant before, and the male partner also has high sperm DNA fragmentation (DFI > 30%), it is recommended to first undergo sperm DNA fragmentation testing and andrological treatment domestically. The cycle should start only after DFI drops below 25%, otherwise, it may affect embryo developmental potential and reduce the number of biopsiable blastocysts.

Practitioner's Observation: An Overseas Coordinator's Perspective

I have worked in an assisted reproduction coordination role for 7 years and have handled many SMA clients' Georgia projects. A common issue is that clients mistakenly believe "third-generation IVF" screens for all genetic diseases, or that "Georgia IVF can screen all genes." In reality, PGT-M is "targeted screening," requiring a testing system to be established for the specific disease. If a client wants to screen for SMA and two other monogenic diseases simultaneously (e.g., thalassemia, deafness), the cost is cumulative based on the number of diseases, and it is necessary to confirm whether the laboratory has the corresponding multiplex testing capability. Additionally, Georgian law does not allow non-medical whole-genome sequence analysis of embryos, so dozens of diseases cannot be screened at once. It is recommended that clients list all genetic diseases they wish to rule out before making a decision and communicate this clearly with the doctor.

Another practical issue: If a client has had multiple failed IVF cycles domestically, it is best to analyze the reasons for failure before going to Georgia. Is it an embryo chromosomal issue, an endometrial factor, or a genetic issue? Do not blindly choose PGT solely because of an SMA carrier diagnosis; first rule out other potential causes affecting pregnancy rates.

Suggestions for Next Steps

If you are considering SMA screening via Georgia IVF, it is recommended to proceed in the following order:

1. Complete SMA genetic testing for both partners as soon as possible (including SMN1 and SMN2 copy numbers) and obtain authoritative reports.
2. Consult at least 2-3 Georgian reproductive centers with the reports, confirm that their PGT-M laboratory can handle the specific gene site, and obtain written agreement on the testing items and costs.
3. Simultaneously complete an assessment of the female partner's ovarian function (AMH, FSH, ultrasound antral follicle count) to evaluate the number of possible egg retrievals.
4. Prepare passports (validity should be at least 14 months beyond the expected menopause date to allow for embryo freezing and future transfer opportunities) and check Georgia's visa requirements (currently, Chinese citizens can enter visa-free for stays up to 90 days).
5. Plan the timeline in advance: Depart after genetic testing, allowing at least 2 months in Georgia for the processes of stimulation, egg retrieval, biopsy, testing, and transfer (a single cycle can take as little as 2.5 months, but consider the time needed for embryo freezing and waiting for test results).

The above content is for medical knowledge popularization only and does not constitute diagnostic or treatment advice. Please consult a formal reproductive center and genetic counseling doctor for specific treatment plans.